Press release
Geron Reports Oral Presentation at ASH Annual Meeting Highlighting Continuous Long-Term Transfusion Independence with Imetelstat Treatment in Lower Risk MDS Patients
≥1 year durable transfusion independence (1-year TI) achieved in 29% of IMerge Phase 2 patients, with a median TI duration of 1.8 years In patients
About this update from Geron Corporation
[{"type":"text","content":"\n\n≥1 year durable transfusion independence (1-year TI) achieved in 29% of IMerge Phase 2 patients, with a median TI duration of 1.8 years\n\n\nIn patients previously treated with luspatercept, 33% achieved 1-year TI\n\n\nStrong evidence of disease modification in patients with 1-year TI as indicated by ≥3g/dL increases in hemoglobin, as well as reductions in SF3B1 variant allele frequency (VAF) that were correlated with longer TI duration and shorter time to onset of TI\n\n\nTop-line results from ongoing IMerge Phase 3 clinical trial expected in early January 2023\n\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nGeron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced results from an oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting on longer follow-up data from the IMerge Phase 2 clinical trial of imetelstat, the Company’s first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS). The data in the presentation focused on the patients who achieved greater than one-year sustained continuous transfusion independence and included their baseline characteristics, clinical benefits and observed safety profile.\n\n“Achievement of one year or more uninterrupted transfusion independence represents significant clinical benefit given the high transfusion burden of the patients in the IMerge Phase 2 trial,” said Faye Feller, M.D., Executive Vice President, Chief Medical Officer of Geron. “The durability of transfusion independence, which was correlated to decreases in mutated cells with variant alleles, provide strong evidence of disease modification with imetelstat treatment. If the data from the Phase 2 are confirmed by the top-line results from IMerge Phase 3, which we expect in early January 2023, imetelstat could transform the lower risk MDS treatment landscape.”\n\nLonger Follow-Up Data from IMerge Phase 2 Clinical Trial in Lower Risk MDS\n\nIMerge Phase 2 is an open label, single arm study to assess the efficacy and safety of imetelstat in transfusion dependent patients with Low or Intermediate-1 risk myelodysplastic syndromes (lower risk MDS), who are relapsed or refractory to prior treatment with erythropoiesis stimulating agents (ESAs). The primary efficacy endpoint is 8-week transfusion independence (TI) rate, which is defined as the ...